Acetylcholine and bradykinin induce paradoxically amplified hypotensive response in hypertensive NO-deficient rats

Physiological Research

Volumn 48, Issue 4, 1999, Pages 249-257

  Gerova M ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Acetylcholine hypotension; Bradykinin hypotension; L NAME; Long term NO synthase inhibition; NO synthase

Indexed keywords

ACETYLCHOLINE; ATROPINE; BRADYKININ; MUSCARINIC RECEPTOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HEART RATE; HYPERTENSION; HYPOTENSION; MALE; NONHUMAN; RAT;

ACETYLCHOLINE; ANIMALS; ATROPINE; BLOOD PRESSURE; BRADYKININ; ENZYME INHIBITORS; HEART RATE; HYPERTENSION; MALE; MUSCARINIC ANTAGONISTS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR;

EID: 0032843582     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. ARNAL JF, EL AMRANI AI, CHATELLIER G, MÉNARD J, MICHEL JB: Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 22: 380-387, 1993.
2. BABÁL P, PECHÁŇOVÁ O, BERNÁTOVÁ I, ŠTVRTINA S: Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia. Histol Histopathol 12: 623-629, 1997.
3. BERNÁTOVÁ I, PECHÁŇOVÁ O, ŠIMKO F: Captopril prevents NO deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Physiol Res 45: 311-316, 1996.
4. CHEN G, SUZUKI H, WESTON AH: Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 95: 1165-1174, 1988.
5. FELETOU M, VANHOUTTE PM: Endothelium dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 93: 515-524, 1988.
6. FOLKOW B, GRIMBY G, THULESIUS O: Adaptive structural changes of the vascular walls in hypertension and their relation to the control of the peripheral resistance. Acta Physiol Scand 44: 255-272, 1958.
7. G-nitro-L-arginine methyl ester. Br J Pharmacol 101: 632-639, 1990.
8. G-nitro-L-arginine methyl ester on vasodilator responses to acetylcholine, 5-N-ethylcarboxamidoadenosine or salbutamol in conscious rats. Br J Pharmacol 103: 1725-1732, 1991.
9. GEROVÁ M, HARTMANNOVÁ B, DOLEŽEL S, JEŽEK L: Long-term inhibition of NO synthase induces cardiac hypertrophy with a decrease in adrenergic innervation. Physiol Res 45: 339-344, 1996.
10. GEROVÁ M, MESÁROŠ Š, KRISTEK F, KITTOVÁ M, MALINSKI T: NO concentration in the periendothelial area of the femoral artery of the dog measured in vivo. Physiol Res 47: 169-175, 1998.
11. IGNARRO LJ, BUGA GM, WOOD KS, BYRNS RE, CHAUDHURI G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84: 9265-9269, 1987.
12. HAEGERTY AM, AALKJER C, BUND SJ, KORSGAGRD N, MULVANY MJ: Small artery structure in hypertension. Hypertension 21: 391-395, 1993.
13. G-nitro-L-arginine in anaesthetized rats. Clin Exp Pharmacol Physiol 25: 510-516, 1998.
14. KOJDA G, KOTTENBERG K, NOACK E: Inhibition of nitric oxide synthase and soluble guanylate cyclase induces cardiodepressive effects in normal rat hearts. Eur J Pharmacol 334: 181-190, 1997.
15. KRISTEK F, GEROVÁ M, DEVÁT L, VARGA I: Remodelling of septal branch of coronary artery and carotid artery in L-NAME treated rats. Physiol Res 45: 329-333, 1996.
16. G-methyl-L-arginine in chronically instrumented conscious dogs. J Appl Physiol 77: 471-475, 1994.
17. MORTON JJ, BEATTIE EC, SPEIRS A, GULLIVER F: Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J Hypertens 11: 1083-1088, 1993.
18. PALMER RMJ, FERRIGE AG, MONCADA S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526, 1987.
19. PECHÁŇOVÁ O, BERNÁTOVÁ I, PELOUCH V, ŠIMKO F: Protein remodelling of the heart in NO deficient hypertension: the effect of captopril. J Mol Cell Cardiol 29: 3365-3374, 1997.
20. REES DD, PALMER RMJ, SCHULZ R, HODSON HF, MONCADA S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101: 746-752, 1990.
21. RIBEIRO MO, ANTUNES E, DE NUCCI G, LOVISOLO SM, ZATZ R: Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 20: 298-303, 1992.
22. SLÁDEK T, GEROVÁ M, ZNOJIL V, DEVÁT L: Morphometric characteristics of cardiac hypertrophy by long-term inhibition of NO synthase. Physiol Res 45: 335-338, 1996.
23. TÖRÖK J, HOLÉCYOVÁ A, BERNÁTOVÁ I, PECHÁŇOVÁ O: Endothelium-dependent responses in hypertension induced by long-term inhibition of nitric oxide synthesis. Pflügers Arch 430: R66, 1995.
24. ZANCHI A, AUBERT JF, BRUNNER HR, WAEBER B: Vascular acetylcholine response during chronic NO synthase inhibition: in vivo versus in vitro. Cardiovasc Res 30: 122-129, 1995.